7 Drugs Approved for Primary Care: Q2 2026

The FDA approved several new or expanded treatment options during the second quarter of 2026 with direct implications for conditions commonly managed or identified in primary care, including obesity, hypertension, diabetes, acne, urinary tract infection, HIV-1 infection, and COVID-19 exposure. The approvals include first-in-class or first-in-category agents, new combination therapies, and options that may affect prescribing conversations, referral decisions, and patient counseling in routine clinical practice.

Among the approvals highlighted in this slideshow are orforglipron (Foundayo^®), an oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related medical problems; baxdrostat (Baxfendy^®), a first-in-class aldosterone synthase inhibitor for adults with uncontrolled hypertension on background therapy; and ensitrelvir (Xocova^®), an oral antiviral approved for postexposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older. Other approvals include doravirine/islatravir (Idvynso^®) for virologically suppressed adults with HIV-1, insulin glargine-aldy (Langlara^®) as an interchangeable biosimilar to insulin glargine, cefepime/zidebactam (Zaynich^®) for complicated urinary tract infections including pyelonephritis, and over-the-counter adapalene/benzoyl peroxide gel for acne in patients aged 12 years and older.